WAU
NBIX icon

Wellington-Altus USA’s Neurocrine Biosciences NBIX Stock Holding History

Wellington-Altus USA’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.2K Hold
305
– – 0.03% 354
2026
Q1 		$51.4K Buy
305
+111
+57% +$14.7K 0.03% 334
2025
Q4 		$27.5K Buy
+194
New +$28.1K 0.02% 417

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wellington-Altus USA's NBIX Position: Q2 2026 in Review

Wellington-Altus USA held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 305 shares worth $40.2K. The position accounts for 0.03% of the portfolio, ranked #354.

Wellington-Altus USA first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. The position peaked at $51.4K in Q1 2026. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Wellington-Altus USA held 305 shares of Neurocrine Biosciences worth $40.2K as of Q2 2026.
  • Wellington-Altus USA left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.03% of Wellington-Altus USA's portfolio in Q2 2026, its #354 holding.
  • Wellington-Altus USA first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Wellington-Altus USA's Neurocrine Biosciences position peaked at $51.4K in Q1 2026.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Wellington-Altus USA's 13F filing for Q2 2026, filed 17 Sep 2026.